Development of Tumor Organoids from Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

Launched by CENTRE FRANCOIS BACLESSE · Sep 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to develop tumor organoids, which are tiny lab-grown versions of tumors, from patients with a type of cancer called undifferentiated primary carcinoma (UPC). The main goal is to use these organoids to help doctors predict how well different treatments might work for individual patients. This could lead to more personalized and effective treatment options for people with UPC.

To be eligible for this trial, participants must be adults diagnosed with undifferentiated primary carcinoma and have a recommendation for their first treatment. They should also have a life expectancy of more than three months and must be able to give their consent to participate. Unfortunately, those who are pregnant or breastfeeding, or who are under legal guardianship, cannot take part. If you join the trial, you will contribute to important research that may help improve treatment approaches for future patients with this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
• • Patient with indication for 1st-line treatment at the time of inclusion.
• • Patient with life expectancy greater than 3 months
• • Patient of legal age
• • Patient affiliated to a social security scheme
• • Signature of informed consent prior to any specific study procedure
• Exclusion Criteria:
• • Persons deprived of their liberty or under guardianship (including curatorship)
• • Pregnant or breast-feeding patient